Sunitinib-induced cardiac hypertrophy and the endothelin axis.
Animals
Cardiomegaly
/ chemically induced
Disease Models, Animal
Endothelin Receptor Antagonists
/ administration & dosage
Endothelins
/ physiology
Female
Fibrosis
Glycolysis
/ drug effects
Hypertension
/ chemically induced
Mice
Mice, Inbred C57BL
Mice, Nude
Precision Medicine
Pyrimidines
/ administration & dosage
Sulfonamides
/ administration & dosage
Sunitinib
/ toxicity
Ventricular Remodeling
/ drug effects
cardiac hypertrophy
cardiotoxicity
endothelin
metabolic imaging.
sunitinib
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
06
2020
accepted:
13
10
2020
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
30
7
2021
Statut:
epublish
Résumé
Anti-angiogenics drugs in clinical use for cancer treatment induce cardiotoxic side effects. The endothelin axis is involved in hypertension and cardiac remodelling, and addition of an endothelin receptor antagonist to the anti-angiogenic sunitinib was shown to reduce cardiotoxicity of sunitinib in mice. Here, we explored further the antidote effect of the endothelin receptor antagonist macitentan in sunitinib-treated animals on cardiac remodeling.
Identifiants
pubmed: 33664864
doi: 10.7150/thno.49837
pii: thnov11p3830
pmc: PMC7914356
doi:
Substances chimiques
Endothelin Receptor Antagonists
0
Endothelins
0
Pyrimidines
0
Sulfonamides
0
Sunitinib
V99T50803M
macitentan
Z9K9Y9WMVL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3830-3838Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
J Clin Invest. 2005 Mar;115(3):527-37
pubmed: 15765134
PLoS One. 2017 Jan 27;12(1):e0169964
pubmed: 28129334
Neth Heart J. 2008 Apr;16(4):129-33
pubmed: 18427637
Mol Pharmacol. 2008 Dec;74(6):1722-8
pubmed: 18815214
Circ Heart Fail. 2016 Nov;9(11):
pubmed: 27810862
Hypertension. 2012 Jan;59(1):151-7
pubmed: 22124432
Eur J Heart Fail. 2018 May;20(5):853-872
pubmed: 29520964
J Clin Invest. 2018 Aug 31;128(9):3716-3726
pubmed: 30124471
Int J Mol Sci. 2019 Jul 02;20(13):
pubmed: 31269778
Lancet. 2011 Dec 3;378(9807):1931-9
pubmed: 22056247
Histochem Cell Biol. 2009 Apr;131(4):471-81
pubmed: 19030868
Nat Biomed Eng. 2018 Feb;2(2):85-94
pubmed: 31015628
Circ Res. 2004 Jan 9;94(1):110-8
pubmed: 14656927
Cardiovasc Res. 2018 Dec 1;114(14):1819-1821
pubmed: 30295759
J Hum Hypertens. 2015 Jan;29(1):1-6
pubmed: 24804791
FASEB J. 2020 Jan;34(1):930-944
pubmed: 31914588
Am J Hypertens. 1995 Nov;8(11):1128-34
pubmed: 8554737
Br J Cancer. 1988 Jul;58(1):109-13
pubmed: 3166888
BJU Int. 2012 Nov;110(10):1455-62
pubmed: 22508007
Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2138-43
pubmed: 17488730
Int J Mol Sci. 2019 May 01;20(9):
pubmed: 31052420
J Physiol. 2006 Jul 1;574(Pt 1):95-112
pubmed: 16690706
Cardiovasc Res. 2013 Oct 1;100(1):63-73
pubmed: 23761402
Theranostics. 2017 Jul 8;7(11):2757-2774
pubmed: 28824714
Toxicol Mech Methods. 2012 Jun;22(5):359-66
pubmed: 22394344
Mol Cell Endocrinol. 2016 Feb 5;421:40-8
pubmed: 26123588
Cardiovasc Res. 2017 Jul 1;113(8):892-905
pubmed: 28371893
Hypertension. 2009 Oct;54(4):839-44
pubmed: 19635990
JACC Heart Fail. 2017 Aug;5(8):543-551
pubmed: 28711447
J Nucl Med. 2013 Apr;54(4):609-15
pubmed: 23426760
J Appl Physiol (1985). 2015 Nov 15;119(10):1233-42
pubmed: 26183480
Exp Mol Med. 2019 Dec 19;51(12):1-13
pubmed: 31857574
J Cardiovasc Pharmacol. 2015 Nov;66(5):457-67
pubmed: 26230396
J Mol Cell Cardiol. 1997 Nov;29(11):2873-92
pubmed: 9405163
J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S49-53
pubmed: 10976782
Int Rev Cell Mol Biol. 2012;294:1-97
pubmed: 22364871
Circulation. 2011 Jan 25;123(3):327-34
pubmed: 21263005
FEBS Lett. 1990 Jul 30;268(1):149-51
pubmed: 2200708
J Am Coll Cardiol. 2001 Feb;37(2):676-85
pubmed: 11216996
Lancet. 2007 Dec 15;370(9604):2011-9
pubmed: 18083403
J Clin Invest. 2010 Feb;120(2):472-84
pubmed: 20071776
Annu Rev Physiol. 1999;61:391-415
pubmed: 10099694
Hypertension. 2010 Oct;56(4):675-81
pubmed: 20733093
Cardiovasc Toxicol. 2015 Jan;15(1):41-51
pubmed: 24984876
Theranostics. 2020 Feb 10;10(8):3518-3532
pubmed: 32206105
Eur J Heart Fail. 2013 May;15(5):482-9
pubmed: 23325019
Circ Res. 2014 Jan 31;114(3):565-71
pubmed: 24481846
J Pharmacol Pharmacother. 2015 Jan-Mar;6(1):53-7
pubmed: 25709357
Cardiology. 2015;130(4):211-20
pubmed: 25791172
J Mol Cell Cardiol. 2014 Aug;73:103-11
pubmed: 24530760
Methods Mol Biol. 2018;1732:321-342
pubmed: 29480485
NPJ Precis Oncol. 2018 May 8;2:13
pubmed: 30202791
Front Physiol. 2019 May 29;10:638
pubmed: 31191343